Literature DB >> 22995839

Therapeutic vaccines: the ultimate personalized therapy?

James L Gulley1.   

Abstract

Personalized therapy is directed at obtaining maximal therapeutic effect on diseased tissue with minimal off-target side effects. Many classes of therapeutics have attempted to reach this ideal, only to fall well short. Therapeutic vaccines represent a novel class of therapies that can induce a dynamic immune response that, in theory, can continue to adapt and expand following initiation of vaccination. This adaptability, through epitope spreading or antigen cascade, can continuously refine a therapeutic immune response, making it more relevant to the patient's tumor. This active, dynamic, iterative process can continue long after the vaccine course has been completed. Recent clinical trials have provided further insight into the clinical activity of therapeutic vaccines, and offer guidance on clinical expectations following vaccine. The ongoing active sculpting of the immune response, along with the lack of significant side effects, uniquely positions therapeutic vaccines as perhaps the ultimate in personalized therapy.

Entities:  

Keywords:  antigen cascade; antigen spreading; cancer vaccine; epitope spreading; immunotherapy; individualized therapy; personalized medicine

Mesh:

Substances:

Year:  2012        PMID: 22995839      PMCID: PMC3667942          DOI: 10.4161/hv.22106

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  20 in total

1.  Abscopal regression of antigen disparate tumors by antigen cascade after systemic tumor vaccination in combination with local tumor radiation.

Authors:  James W Hodge; Hadley J Sharp; Sofia R Gameiro
Journal:  Cancer Biother Radiopharm       Date:  2012-01-27       Impact factor: 3.099

2.  Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant.

Authors:  Robert J Lechleider; Philip M Arlen; Kwong-Yok Tsang; Seth M Steinberg; Junko Yokokawa; Vittore Cereda; Kevin Camphausen; Jeffrey Schlom; William L Dahut; James L Gulley
Journal:  Clin Cancer Res       Date:  2008-08-15       Impact factor: 12.531

3.  Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer.

Authors:  James L Gulley; Philip M Arlen; Anne Bastian; Steven Morin; Jennifer Marte; Patricia Beetham; Kwong-Yok Tsang; Junko Yokokawa; James W Hodge; Cynthia Ménard; Kevin Camphausen; C Norman Coleman; Francis Sullivan; Seth M Steinberg; Jeffrey Schlom; William Dahut
Journal:  Clin Cancer Res       Date:  2005-05-01       Impact factor: 12.531

Review 4.  Endpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccines.

Authors:  Marijo Bilusic; James L Gulley
Journal:  Cancer Immunol Immunother       Date:  2011-11-26       Impact factor: 6.968

Review 5.  Immunotherapy for prostate cancer: recent advances, lessons learned, and areas for further research.

Authors:  James L Gulley; Charles G Drake
Journal:  Clin Cancer Res       Date:  2011-06-15       Impact factor: 12.531

6.  Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy.

Authors:  Wilfred D Stein; James L Gulley; Jeff Schlom; Ravi A Madan; William Dahut; William D Figg; Yang-Min Ning; Phil M Arlen; Doug Price; Susan E Bates; Tito Fojo
Journal:  Clin Cancer Res       Date:  2010-11-24       Impact factor: 12.531

7.  Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.

Authors:  Ravi A Madan; Mahsa Mohebtash; Philip M Arlen; Matteo Vergati; Myrna Rauckhorst; Seth M Steinberg; Kwong Y Tsang; Diane J Poole; Howard L Parnes; John J Wright; William L Dahut; Jeffrey Schlom; James L Gulley
Journal:  Lancet Oncol       Date:  2012-02-10       Impact factor: 41.316

Review 8.  Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment.

Authors:  Thomas F Gajewski
Journal:  Clin Cancer Res       Date:  2007-09-15       Impact factor: 12.531

Review 9.  Synergizing radiation therapy and immunotherapy for curing incurable cancers. Opportunities and challenges.

Authors:  James W Hodge; Chandan Guha; Jacques Neefjes; James L Gulley
Journal:  Oncology (Williston Park)       Date:  2008-08       Impact factor: 2.990

10.  Epitope spreading contributes to effective immunotherapy in metastatic melanoma patients.

Authors:  Nicola Hardwick; Benjamin Chain
Journal:  Immunotherapy       Date:  2011-06       Impact factor: 4.196

View more
  17 in total

1.  Antigen-Specific CD8 Lytic Phenotype Induced by Sipuleucel-T in Hormone-Sensitive or Castration-Resistant Prostate Cancer and Association with Overall Survival.

Authors:  Emmanuel S Antonarakis; Eric J Small; Daniel P Petrylak; David I Quinn; Adam S Kibel; Nancy N Chang; Erica Dearstyne; Matt Harmon; Dwayne Campogan; Heather Haynes; Tuyen Vu; Nadeem A Sheikh; Charles G Drake
Journal:  Clin Cancer Res       Date:  2018-06-01       Impact factor: 12.531

2.  Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome.

Authors:  Debraj GuhaThakurta; Nadeem A Sheikh; Li-Qun Fan; Harini Kandadi; T Craig Meagher; Simon J Hall; Philip W Kantoff; Celestia S Higano; Eric J Small; Thomas A Gardner; Kate Bailey; Tuyen Vu; Todd DeVries; James B Whitmore; Mark W Frohlich; James B Trager; Charles G Drake
Journal:  Clin Cancer Res       Date:  2015-02-03       Impact factor: 12.531

3.  Surgical cytoreduction restores the antitumor efficacy of a Listeria monocytogenes vaccine in malignant pleural mesothelioma.

Authors:  Gregory T Kennedy; Brendan F Judy; Pratik Bhojnagarwala; Edmund K Moon; Zvi G Fridlender; Steven M Albelda; Sunil Singhal
Journal:  Immunol Lett       Date:  2015-05-18       Impact factor: 3.685

Review 4.  Antigenic variability: Obstacles on the road to vaccines against traditionally difficult targets.

Authors:  R Servín-Blanco; R Zamora-Alvarado; G Gevorkian; K Manoutcharian
Journal:  Hum Vaccin Immunother       Date:  2016-06-13       Impact factor: 3.452

5.  Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer.

Authors:  James L Gulley; Ravi A Madan; Kwong Y Tsang; Caroline Jochems; Jennifer L Marté; Benedetto Farsaci; Jo A Tucker; James W Hodge; David J Liewehr; Seth M Steinberg; Christopher R Heery; Jeffrey Schlom
Journal:  Cancer Immunol Res       Date:  2013-11-04       Impact factor: 11.151

Review 6.  Adding fuel to the fire: immunogenic intensification.

Authors:  Geraldine O'Sullivan Coyne; James L Gulley
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 7.  Therapeutic vaccines as a promising treatment modality against prostate cancer: rationale and recent advances.

Authors:  B Harpreet Singh; James L Gulley
Journal:  Ther Adv Vaccines       Date:  2014-09

Review 8.  Opportunities in immunotherapy of ovarian cancer.

Authors:  G Coukos; J Tanyi; L E Kandalaft
Journal:  Ann Oncol       Date:  2016-04       Impact factor: 32.976

9.  Engineered red blood cells as an off-the-shelf allogeneic anti-tumor therapeutic.

Authors:  Xuqing Zhang; Mengyao Luo; Shamael R Dastagir; Mellissa Nixon; Annie Khamhoung; Andrea Schmidt; Albert Lee; Naren Subbiah; Douglas C McLaughlin; Christopher L Moore; Mary Gribble; Nicholas Bayhi; Viral Amin; Ryan Pepi; Sneha Pawar; Timothy J Lyford; Vikram Soman; Jennifer Mellen; Christopher L Carpenter; Laurence A Turka; Thomas J Wickham; Tiffany F Chen
Journal:  Nat Commun       Date:  2021-05-11       Impact factor: 14.919

Review 10.  Immunotherapy and therapeutic vaccines in prostate cancer: an update on current strategies and clinical implications.

Authors:  B Harpreet Singh; James L Gulley
Journal:  Asian J Androl       Date:  2014 May-Jun       Impact factor: 3.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.